Mumbai: The Nifty Pharma Index has touched an all time high of 25,043 on Wednesday, May 20 even as the benchmark Nifty50 declined 0.14% to close at 23,585 amid challenges with the Middle East conflict. 

The Pharma index has outperformed the headline index by a wide margin, where the Nifty Pharma index delivered a 15% gain in a year while the Nifty 50 declined 4% during the same period. 

Why Pharma is Back in Focus

This rally has come at a time despite the geopolitical challenges and has depended on the macroeconomic shifts made.

  • The weakening rupee advantage: With the Indian Rupee at a lifetime low of 96.96 against the US Dollar, this has been a boon for the sector which has relied on exports to the US and Europe for its growth. 
  • Favored for safety: Various  Portfolio Management Service (PMS) houses and institutional desks have been favouring pharma stocks as pharma revenues remain fairly consistent with hardly any impact from fuel-driven inflation.

Top Outperformers

This outperformance has seen various high volocity large cap players witness their own set of rallies. 

  1. Zydus Lifesciences: Its shares surged 5.71% to reach Rs.1,091 as the company announced a massive Rs.1,100 crore share buyback with a premium price of Rs.1,150 per share. 
  2. Mankind Pharma: Shares rose 2.38% after its net profit rose 32% year on year due to robust market share gains across Tier 2 cities.
  3. Gland Pharma: The company’s shares have been in focus following its 97% year-on-year net profit gain driven by strong gains in its US business.

Abizar has been writing before AI started to take over your lives! His expertise lies in analysing diverse perspectives and simplifying them for laymen. Beyond writing, storytelling and editing, he enjoys running, learning and enjoying the outdoors.

HEgoogleNews